Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease

Simple item page
dc.contributor.authorTenikoff, D.
dc.contributor.authorMurphy, K.
dc.contributor.authorLe, M.
dc.contributor.authorHowe, P.
dc.contributor.authorHowarth, G.
dc.date.issued2005
dc.descriptionThe original publication can be found at www.springerlink.com
dc.description.abstractLyprinol (Pharmalink International), the stabilised lipid extract of the New Zealand green-lipped mussel, is currently used to relieve symptoms of arthritis. We investigated the effect of pretreatment with Lyprinol (LYP) on experimentally induced inflammatory bowel disease (IBD) in mice. Methods. Male C57BL/6 mice (aged 6 weeks) were gavaged daily for 13 days with (150μl) olive oil (OO; n = 7), fish oil (FO; n = 8), or LYP (n = 8). Mice consumed 2% dextran sulfate sodium (DSS) for 6 days, starting on day 7. Body weight and disease activity index (DAI) scores were recorded daily. Colonic damage was determined by histopathology. Colonic inflammation was quantified by myeloperoxidase (MPO) activity. Results. LYP treatment significantly (P = 0.05) reduced body weight loss, DAI scores, crypt area losses, and cecum and colon weights, compared with FO treatment. MPO activity was not significantly affected by any treatment. Conclusions. These findings provide preliminary evidence that Lyprinol may be potentially useful in ameliorating symptoms of IBD. The benefit, however, is unlikely to be due to the omega-3 fatty acid content. Doseresponse evaluation of Lyprinol in experimental IBD is warranted.
dc.description.statementofresponsibilityDanik Tenikoff, Karen J. Murphy, Maria Le, Peter R. Howe and Gordon S. Howarth
dc.identifier.citationJournal of Gastroenterology, 2005; 40(4):361-365
dc.identifier.doi10.1007/s00535-005-1551-x
dc.identifier.issn0944-1174
dc.identifier.issn1435-5922
dc.identifier.orcidHowe, P. [0000-0001-6546-7742]
dc.identifier.orcidHowarth, G. [0000-0001-6979-6084]
dc.identifier.urihttp://hdl.handle.net/2440/27501
dc.language.isoen
dc.publisherSpringer-Verlag
dc.rights© Springer-Verlag 2005
dc.source.urihttps://doi.org/10.1007/s00535-005-1551-x
dc.subjectNew Zealand green-lipped mussel
dc.subjectulcerative Colitis
dc.subjectfish oil
dc.subjectdextran sulfate sodium
dc.subjectmice
dc.titleLyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Molecular and Biomedical Science publications